The notable anti-PD-1 (nivolumab and pembrolizumab) and anti-PD-L1 (atezolimumab and avelumab) have further expanded the applicability of checkpoint inhibitors to various other cancers, including HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.